Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA
Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical needs, today announces that data on the company's leading program fostroxacitabine bralpamide (fostrox) and its potential effect on hepatocellular carcinoma (HCC), will be presented at the International Liver Cancer Association (ILCA) Annual Meeting, September 7-9 in Amsterdam. An abstract, titled "Combinations of fostrox (MIV-818), a novel nucleotide prodrug, with lenvatinib or sorafenib, shows increased efficacy in non-clinical